GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
GRAIL, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.42+4.61 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
GRAIL, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening revenue | $42.64M | $39.83M | $42.28M | $32.81M | $34.38M | $29.13M | $31.55M | $25.37M | $28.16M | $23.54M | – | – | 95.4% | +24.0% |
| Development Services | $2.05M | $953.00K | $1.32M | $3.39M | $1.17M | $2.70M | $6.70M | $3.28M | $3.81M | $3.18M | $7.67M | $3.98M | 4.6% | +75.5% |
By region
From the segment and revenue-disaggregation notes of Grail's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.